Biocom - Life Sciences Association of California
San Diego  |   Los Angeles  |   Washington, DC  |   Tokyo

Public Policy Newsletter

usa flag

State Affairs

Legislation Affecting Industry Advances in Sacramento
The past month has seen a swarm of activity on bills affecting the industry as legislators faced a deadline to get most legislation passed out of the house of origin.  

SB 17, a bill which would require drug manufacturers to give advance notice of proposed price increases and require publication of proprietary pricing strategies, was approved by the State Senate on a largely party line vote of 28-10 on May 30.  It is scheduled for its first hearing in the State Assembly on June 27.  The industry has offered substantive amendments to the author in a good faith effort to forge a compromise.

AB 265, which would ban co-pay coupons and other patient assistance vehicles in many cases, was approved by the State Assembly by a 51-15-14 margin on May 31.  The industry also continues to have a dialogue with the author’s office in advance of a scheduled June 28th hearing in the Senate Health Committee.  

Finally, SB 790, which would ban “gifts” such as informational dinners for physicians and other providers, and as currently written would likely adversely affect the availability of clinical trials conducted in California, was approved by the State Senate by a margin of 23-13-4. This bill is scheduled to be heard in the Assembly Health Committee on June 27, although a brief postponement is likely on this legislation as stakeholders continue discussions on this proposal.

These and all bills Biocom has taken a formal position on can be found here, along with Biocom’s support or oppose correspondence.  Please contact Jimmy Jackson for further information.
Upcoming Public Policy Events
Los Angeles Area Facilities/EH&S Committee Kickoff
June 27, 2017
12:00 PM
Joint Biocom/IEA Meeting: Prop 65 Update
July 18, 2017
11:30 AM